MOTS-c
MetabolicAlso known as: Mitochondrial Open Reading Frame of the 12S rRNA-c, MOTS-c peptide, mitochondrial peptide
MOTS-c is an early-stage research peptide with no human clinical trials completed. All data comes from in vitro and animal studies except limited observational human data. Not approved for human use. For research and informational purposes only.
Overview
MOTS-c is a mitochondria-derived peptide encoded in the 12S ribosomal RNA gene of mitochondrial DNA. It translocates to the nucleus under metabolic stress and regulates gene expression related to insulin sensitivity, fat oxidation, and cellular homeostasis. It is one of the most novel peptides in longevity and metabolic research.
Research Summary
MOTS-c activates AMPK and regulates the folate cycle and methionine metabolism. In rodent models it has reversed high-fat-diet-induced insulin resistance, reduced obesity, and extended lifespan in aged mice. A landmark 2021 study showed MOTS-c levels decline with age and exogenous administration improved physical performance and metabolic health in aged mice. Human studies are emerging, with observational data showing higher circulating MOTS-c in centenarians versus average-aged adults.
Dosing Range
low
5mg
moderate
10mg
high
20mg
Units: mg · Frequency: 3x weekly or daily (research protocols vary significantly)
Dosing ranges are aggregated from preclinical research and community protocols. Not medical dosing guidance.
Administration Routes
Reconstitution Notes
Reconstitute with bacteriostatic water. Common concentration: 10mg per 1mL BAC water. Highly sensitive to degradation — store lyophilized powder at -20°C, reconstituted solution at 2–8°C. Use within 14 days of reconstitution. Do not freeze reconstituted solution.Step-by-step reconstitution guide →
Reported Side Effects
- Generally well-tolerated in animal studies
- Injection site reactions
- Hypoglycemia risk in diabetics or those on insulin sensitizers
- Human side effect data is very limited — this is an early-stage research compound
Research Papers
Community Experiences
Aggregated from public forums. Anecdotal — not clinical evidence.
Longevity-focused discussion on MOTS-c as a mitochondrial anti-aging intervention.
View original threadOverview
MOTS-c stands for Mitochondrial Open Reading Frame of the 12S rRNA-c. Unlike all other peptides in the human body — which are encoded in nuclear DNA — MOTS-c is encoded directly in mitochondrial DNA. This makes it one of only a handful of known mitochondria-derived peptides (MDPs), a newly characterized class of signaling molecules.
It was first characterized by Pinchas Cohen's lab at USC in 2015, and research has accelerated significantly since 2019.
Why MOTS-c Is Different
Most metabolic peptides work peripherally — binding receptors on fat cells, muscle, or the liver. MOTS-c is unusual: under metabolic stress (exercise, fasting, caloric restriction), it translocates from mitochondria to the nucleus and directly regulates gene expression. It essentially acts as a mitochondrial stress signal to the rest of the cell.
Key Research Findings
Insulin sensitivity (2015 — Cell Metabolism) The landmark founding paper showed MOTS-c activates AMPK via the folate-methionine-AICAR pathway, reversing insulin resistance in high-fat-diet mice. This placed MOTS-c alongside metformin in the AMPK activation category.
Exercise mimetic (2021 — Nature Communications) MOTS-c levels rise during exercise. Exogenous administration to aged (12-month) mice improved physical performance comparable to exercised younger mice. The authors proposed MOTS-c may partially mediate exercise benefits at the cellular level.
Longevity association (2019 — Aging) Centenarians (100+ year old humans) have measurably higher circulating MOTS-c levels compared to average middle-aged adults, suggesting a possible role in extreme longevity.
Mechanism Summary
| Pathway | Effect | |---------|--------| | AMPK activation | Improves insulin sensitivity, fat oxidation | | Folate cycle regulation | Reduces oxidative stress, supports methylation | | Nuclear gene expression | Coordinates mitochondrial-nuclear stress response | | Muscle homeostasis | Preserves muscle function with aging |
Research Context
MOTS-c is approximately 10 years behind BPC-157 or TB-500 in terms of research volume. There are no completed human clinical trials as of 2026. Community protocols are extrapolated from rodent dosing (scaled by body weight) with significant uncertainty. This is genuinely frontier research.
Its intersection with exercise biology, longevity, and metabolic disease makes it one of the most watched peptides in the research community despite its early stage.
Want to calculate your dose? Use the dosing calculator →